Impact ledger
iShares Biotechnology ETF (IBB): the developments shaping its investment case
Follow the evidence affecting iShares Biotechnology ETF. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research iShares Biotechnology ETF · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-03
NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival
Channel: Positive sentiment spillover for the biotechnology sector, particularly for companies with oncology pipelines or those developing targeted therapies.
Bullish· 1-5d
2026-09-25
ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share
Channel: Improved sector sentiment and investor confidence. Similar to XBI, a strong biotech IPO can indicate a healthier funding environment and investor interest for the broader biotechnology industry, potentially attracting capital to diversified biotech ETFs.
Bullish· 1-3m
2026-09-21 · 2 reports
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study
Channel: Improved sentiment for the biotechnology sector, particularly for companies with clinical-stage assets, due to a successful trial outcome from a constituent company.
Bullish· 1-5d
Event impact log
17 events mapped to IBB since 2026-08-12. Evidence through 2026-09-29.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-29 | Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial | Similar to XBI, positive clinical trial news from a smaller constituent can provide a slight positive sentiment boost to the broader biotech sector, though the direct impact is negligible. | Bullish | 1-3m | 0.10 |
| 2026-09-25 | ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share | Improved sector sentiment and investor confidence. Similar to XBI, a strong biotech IPO can indicate a healthier funding environment and investor interest for the broader biotechnology industry, potentially attracting capital to diversified biotech ETFs. | Bullish | 1-3m | 0.50 |
| 2026-09-24 | Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology | Indirect impact through CLNN's weighting in the ETF and broader sector sentiment. Significant news from a component company can slightly influence the ETF, especially if it sets a trend for similar assets or technologies. | watch | 1-3m | 0.20 |
| 2026-09-23 | Longeveron Announces Exploration of All Options to Maximize Shareholder Value Following Phase 2b Trial Results | Minor sentiment spillover to the broader biotechnology sector, reinforcing perceived risks. | Bearish | 1-5d | 0.10 |
| 2026-09-22 | XFLH Capital Corporation signs letter of intent for business combination with Renogen Biolab Inc. | Indirect exposure to the biotechnology sector. A successful de-SPAC of a biotech company could contribute to overall sector sentiment, potentially influencing the ETF's performance. | watch | 3-12m | 0.20 |
| 2026-09-21 | Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study | Improved sentiment for the biotechnology sector, particularly for companies with clinical-stage assets, due to a successful trial outcome from a constituent company. | Bullish | 1-5d | 0.10 |
| 2026-09-21 | Ionis slides over 40% year-to-date following late-stage clinical setbacks | Sector-wide sentiment. Similar to XBI, but IBB typically has a larger cap bias, so the direct impact from IONS might be slightly less pronounced, but the sentiment effect remains. | Bearish | 1-5d | 0.15 |
| 2026-09-20 | Electra Therapeutics Sets Terms for $347M Nasdaq IPO | Broader sentiment indicator for the biotechnology sector, particularly for development-stage companies. | watch | 1-3m | 0.20 |
| 2026-09-19 | Electra Therapeutics IPO — $347M | Sector sentiment and capital allocation trends. A successful IPO could signal investor appetite for biotech, while a struggling one might indicate caution. | watch | 1-3m | 0.10 |
| 2026-09-16 | COSCIENS Biopharma Inc. Convertible — $4.4M | Indirect sentiment and capital availability for the broader biotech sector. Similar to XBI, this event provides a data point on financing conditions. | watch | 1-3m | 0.20 |
| 2026-09-03 | NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival | Positive sentiment spillover for the biotechnology sector, particularly for companies with oncology pipelines or those developing targeted therapies. | Bullish | 1-5d | 0.50 |
| 2026-09-02 | TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy | Sector sentiment, capital allocation trends, small-cap biotech performance. | watch | 1-3m | 0.10 |
| 2026-08-21 | Werewolf Therapeutics and Ambros Therapeutics announce merger agreement and concurrent $150 million private placement | Sector sentiment, increased M&A activity indicating potential for further consolidation. | Bullish | 1-5d | 0.30 |
| 2026-08-21 | Werewolf Therapeutics, Inc. to Acquire Ambros Therapeutics, Inc. ($548M) | Indirect impact through sector sentiment. M&A activity can signal health or consolidation trends within the broader biotech industry. | watch | 1-5d | 0.20 |
| 2026-08-19 | Vogenx, Inc. IPO — $12M | A successful IPO in the biotech sector, especially with strong over-allotment exercise, can signal positive investor sentiment for the broader industry, potentially leading to minor inflows or improved sentiment for biotech ETFs. | Bullish | 1-5d | 0.10 |
| 2026-08-17 | Valion Bio, Inc. Follow-On — $1.5M | Indirect sentiment indicator for the biotech sector's funding environment. Continued private investment suggests a healthy ecosystem for innovation and potential future M&A targets. | Bullish | 1-3m | 0.20 |
| 2026-08-12 | Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study | Sentiment boost for the broader biotechnology sector. Similar to XBI, IBB tracks biotech companies and benefits from positive industry-specific news. | Bullish | 1-5d | 0.40 |
Continue this research
Build your iShares Biotechnology ETF investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the IBB entity page →